Literature DB >> 28704124

β cell function and insulin resistance in lean cases with polycystic ovary syndrome.

Arunkumar R Pande1,2, Ashwani Kumar Guleria3,4, Sudhanshu Dev Singh5, Manoj Shukla3, Preeti Dabadghao3.   

Abstract

Obesity is a major factor in development of insulin resistance (IR) and metabolic features in polycystic ovary syndrome (PCOS) patients. Nearly two-thirds patients with PCOS (30 of 37 confirmed cases of PCOS) in our previous community based study were lean, in contrast to Caucasians. Metabolic parameters including IR and β cell function have not been characterized well in this group of lean PCOS. To study the metabolic features including IR and β cell function in lean PCOS patients, 53 patients with BMI, <23 kg/m2 were compared with 71 obese PCOS and 45 age and body mass index matched controls. Lean patients had similar β cell function and IR as compared to controls and obese patients, though the latter group had more metabolic abnormality. Fasting c-peptide and its ratio to glucose were significantly higher in lean patients compared to controls. In subset of subjects with five point OGTT, disposition index and Matsuda index (MI) showed significant negative correlation with BMI and blood pressure. MI also negatively correlated with waist, WHR, and HOMAB. High fasting C-peptide is probably a class effect as is seen in both lean and obese PCOS.

Entities:  

Keywords:  OGTT; PCOS; fasting C-peptide; insulin resistance; lean

Mesh:

Substances:

Year:  2017        PMID: 28704124     DOI: 10.1080/09513590.2017.1342165

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  1 in total

1.  Sex Differences in Hypercortisolism and Glucose-Metabolism Disturbances in Patients with Mild Autonomous Cortisol Secretion: Findings From a Single Center in China.

Authors:  Ru Ouyang; Yaqi Yin; Jie Wang; Wanlu Su; Li Zang; Kang Chen; Jin Du; Zhaohui Lyu; Jingtao Dou; Yiming Mu; Weijun Gu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.